Urothelial carcinoma (UC) remains a common cause of cancer-related death, representing
the fourth most frequently diagnosed solid tumor, worldwide [1]. Around 25% of patients with …

Urothelial carcinoma (UC) is the second most common malignancy of the genitourinary
system and the sixth most common cancer in the United States. The overall incidence of UC …

Urothelial cell carcinoma (UC) is one of the most common cancers and one of the most
deadly. Metastatic UC is particularly hard to treat, because it is typically diagnosed when …

Background Limited data compare first-line carboplatin-based chemotherapy and immune
checkpoint blockade in cisplatin-ineligible metastatic urothelial carcinoma (mUC) patients …

The durability of response and general tolerability of checkpoint blockade has transformed
the treatment of metastatic urothelial carcinoma. However, only a minority of patients …

Context Platinum-based combination chemotherapy is the standard treatment for advanced
or metastatic urothelial carcinoma (AMUC). However, data comparing the efficacy of different …

Objectives: To examine patient and disease characteristics, toxicity, and clinical outcomes
for patients with advanced urothelial carcinoma (aUC) who are rechallenged with immune …

Aim This narrative review describes current guidelines for treating NMIBC, provides an
overview of the principle behind immune checkpoint inhibition, and summarizes current …

Urothelial bladder cancer displays a high number of somatic mutations that render these
tumors more responsive to immunotherapy. Several immunotherapeutic agents were …

Lay Summary Despite longer survival with immune checkpoint inhibitors targeting
programmed cell death protein 1 (PD‐1)/programmed cell death–ligand 1 (PD‐L1) …